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Stereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in
organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation
therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), in the clinic due to advances in precise positioning and
targeting. Dramatic improvements in tumor control have been demonstrated; however, our knowledge of normal tissue biology
response mechanisms to large fraction sizes is lacking. Herein, we will discuss how SABR can induce cellular expression of MHC I,
adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and
death receptors to enhance antitumor immune responses.
1. Introduction
Stereotactic radiosurgery (SRS) was originally developed for
the treatment of intracranial tumors and has demonstrated
clinical effectiveness in treating a variety of benign and
malignant conditions. Its extracranial counterpart, stereotac-
tic body radiation therapy (SBRT), also known as stereotactic
ablative radiotherapy (SABR), has more recently shown
efficacy for the treatment of tumors in organs such as
the liver and lung. The potential for using SABR is likely
greater than for SRS given the larger volume of potential
indications outside the central nervous system. Technology,
rather than biology, is driving the rapid adoption of SABR
in the clinic due to advances in precise positioning, motion
control, dosimetry, and precise targeting with image guid-
ance. Dramatic improvements in tumor control have been
demonstrated in several studies due to the demonstration
that very potent dose can be delivered by use of the
mentioned technology. However, our knowledge of normal
tissue biology response mechanisms to large fraction sizes is
relatively lacking compared to conventional fractionation.
2. Radiobiologic Considerations
A fundamental issue in SABR is whether classical radiobi-
ologic modeling with the linear-quadratic (LQ) model is
a valid method to assess the biologically effective dose at
the high doses typically encountered in radiosurgery. This
point was debated in back-to-back papers in seminars in
radiation oncology [1, 2], where Brenner argued that LQ
formalism was appropriate whilst Kirkpatrick and colleagues
suggested it was inappropriate. Brenner’s argument is based
on the robustness of the LQ model to predict fractionation
and dose-rate effects in experimental models in vitro and in
vivo at doses up to 10Gy. This conclusion is based on the
premise that cell killing is the dominant process mediating
the radiotherapeutic response for both early and late effects
including vascular effects. Brenner argued that, to date, there
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is no evidence of problems when LQ has been applied in the
clinic.
However, this was the crux of Kirkpatrick and colleagues’
argument. They noted multiple studies demonstrating that
the administration of a single high dose of radiation in vivo
had a much greater effect than predicted by the LQ model;
they cited several examples including Leith et al. [3] who
calculated that the dose to obtain a high probability of tumor
control for brain lesions would be at least 25 to 35Gy using
the LQ model, which was much higher than the observed
clinically effective radiosurgical dose, which was in the range
of 15–20Gy. Kirkpatrick maintained that there was a discon-
nect between in vitro cell survival data and observed clinical
data which suggests that there is more than one mechanism
of radiation damage and that these operate differentially at
low and high doses. In addition, Kirkpatrick argues that the
LQ model does not effectively address the potential existence
of radioresistant cancer stem cells, which may require a
threshold dose to be crossed before their death is triggered.
Several authors have proposed alternate models to the
LQ. In all cases, they argue that the LQmodel was intended as
a low dosemathematical representation of the data constitut-
ing the survival curve [4, 5]. As most survival curves demon-
strate a curvilinear “shoulder” followed by a linear portion
on a linear log scale, the high-dose trend to endlessly curve
associated with the LQ model overpredicts survival at high
dose per fraction from a purely mathematical perspective.
In the case of the universal survival curve of Park et al. [5],
the strength of the LQ in the low dose realm is exploited but
abandoned for the linear multitarget model in the high-dose
realm. Thus, the in vitro survival curve has goodness of fit in
all clinically significant ranges including the ablative range
characteristic of SABR. Admittedly, none of the proposed
mathematical models properly account for in vivo effects
including vascular and immune contribution to cell death.
3. The Role of Tumor Stroma
As stated above, the accepted rationale for radiotherapy (RT)
is based on causing lethal DNA damage to tumor cells and
the tumor-associated stroma. There is unequivocal evidence
which has been presented by Fuks and colleagues that the
tumor stroma plays an important role in the response to high
dose per fraction radiation treatment. They demonstrated
that vascular endothelial cell apoptosis is rapidly activated
above 10Gy per fraction [6], and that the ceramide pathway
orchestrated by acid sphingomyelinase (ASMase) operates
as a rheostat that regulates the balance between endothelial
survival and death and thus tumor response [7]. These
studies relied heavily on mice that had ASMase knocked out
in all tissues; the authors have countered the argument that
defective immune system that is known to occur in ASMase
−/−mice [8] influenced their observations [6].
Damage to vascular/stromal elements in tumors has also
been observed around 2 weeks after radiation exposure that
was less dependent on size of dose per fraction [9]. Patholog-
ical observations show profound changes in vasculature after
radiosurgery and from studies on arteriovenous malforma-
tions [10], where obliteration of abnormal vasculature occurs
months after irradiation, but is rarely seen below single doses
of 12Gy climbing steeply with increasing doses above this
threshold.
In terms of the infiltrating immune cell component of
tumor stroma, conventional RT has traditionally been
viewed as immunosuppressive [11], but the systemic effects
of both cancer and local radiotherapy of cancer on the
immune system are clearly more complex than this. Al-
though lymphocyte radiosensitivity is well recognized, the
effects of different doses and delivery methods on systemic
and locoregional naive, effector, or regulatory T cell or other
immunologically relevant populations is still the subject of
debate [12, 13]. Several authors have investigated the poten-
tial immunomodulatory effects of localized RT on tumors
resulting in conflicting reports as to whether these responses
promote or interfere with tumor reduction [14–16]. This
dualism is something that is to be expected and is inherent in
a system that has to promote both destruction of pathogens
and tissue healing while regulating anti-self reactivity. It is
also possible that the more positive effects seen in colorectal
cancer where the immune score was significantly associated
with differences in disease-free, disease-specific, and overall
survival [17] are in part a reflection of additional microbial
challenges that may not be present in other sites.
4. Direct Interaction between Radiation,
Tumor Cells, and the Immune System
Several lines of evidence have suggested direct immune
modulation of immune cells by RT [15, 18–22]. Apetoh et al.
showed that radiation can trigger signals that stimulate toll-
like receptor 4 on antigen presenting dendritic cells (DCs)
[18], Liao has shown that irradiation of DC can enhance
presentation of antigenic peptides by the exogenous pathway
and is a maturation signal, while inhibiting internal antigen
processing [21], and Merrick has shown a decrease in IL-
12 production that has a negative effect on presentation
[15]. Several reports have shown increased expression of
MHC class I and coaccessory molecules after radiation
of both tumor and host cells, while Chakraborty et al.
[19] reported a direct effect of radiation on tumors by
modifying the phenotype of tumor cells to render themmore
susceptible to vaccine-mediated T-cell killing, and others
have shown that radiation-induced changes in the tumor
immune microenvironment to promotes greater infiltration
of immune effector cells [22] (Figure 1).
5. Mechanisms of Radiation Driven
Tumor Immunology
The early report of Stone [23] that the immune system can
dramatically alter the dose required to obtain local tumor
control has been updated by Lee and colleagues, who showed
that CD8+ T cells could be responsible for the therapeutic
effects of ablative radiation [24]. The delivery of an ablative
dose of radiation of 15–25Gy was found to cause a significant
increase in T-cell priming in draining lymphoid tissue,
leading to reduction or eradication of the primary tumor or
distant metastasis in a CD8+ T-cell dependent fashion in an
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Figure 1: Confluence of SABR and Immunotherapy. Apoptosis can be initiated by SABR-induced DNA damage and upregulation of the p53
tumor suppressor gene. In addition, apoptosis can be triggered by SABR-induced damage to the cellular lipid membrane, which can induce
ceramide formation and activate the SAPK/JNK signaling pathway. Thus, SAPK/JNK can upregulate PKR expression, which can induce
MHC and cytokines via NF-κB. SABR can induce cellular expression of MHC Class I, adhesion molecules, costimulatory molecules, heat
shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors.
animal model. While conventional 2Gy doses seem inferior
at generating such responses, higher sized dose fractions may
be better than single doses [25].
The possibility that there may be a certain dose per
fraction that is optimal for stimulating radiation adjuvan-
ticity is of relevance to mechanism of radiation-induced
immune stimulation and clinical practice. Conventional
RT has already been shown to enhance tumor-specific T-
cell responses [26], but such responses are likely of little
clinical relevance and surely can be improved upon by
optimizing dose delivery and integrating RT with modern
immunotherapeutic strategies.
Radiation can not only kill tumor cells releasing tumor
antigens and molecules with what are collectively called
damage-associated molecular patterns (DAMPs) that exert
various immunomodulatory effects including induction of
the expression of cytokines, chemokines, and release of in-
flammatory mediators [27–30] (Figure 1). Although pro-
inflammatory cytokines generally are produced by higher
doses than are conventionally used in RT, there may be an
accumulating effect [31]. Radiation also increases the per-
meability of the local vasculature either directly or through
cytokine production that leads to recruitment of circulating
leukocytes into surrounding tissues including antigen-pre-
senting cells and effector T cells [32–34]. Thus, a radiation-
induced proinflammatory microenvironment within irra-
diated tumors could provide DCs with maturation inducing
stimuli critical for eliciting effective antigen presentation.
The obverse of this is that radiation can stimulate production
of suppressor myeloid cells [35] and Treg cells [36] in a dose-
dependent manner that presumably aim to dampen and
contain tissue damage and that can be highly immuno-
suppressive. Thus, to “unmask” the more positive aspects of
radiation killing on immunity, it may be necessary to target
and impair these natural defenses.
Advances in the understanding of the mechanisms that
regulate the development of antitumor immunity, as well
as improved knowledge of the complex effects of radiation
on tissues [37], have revived interest in the possibility of
combining radiation and immune-based therapies to achieve
a better local and systemic tumor control [28–31]. Since
William Coley started treating patients at the end of the 19th
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century with bacterial toxins, there have been waves of enthu-
siasm promoting immunotherapy for the treatment of can-
cer. The introduction of cytokines, in particular interleukin-
2 (IL-2), for cancer treatment was a major clinical effort that
had modest success. Until recently, however, these efforts
have been hampered by a lack of molecular definition of
tumor antigens, a means of delivering them effectively, and
a sensitive and reliable way to measure responses.
This situation changed with the molecular cloning of
human tumor-associated antigens that could be recognized
by T cells, the ability to culture powerful antigen presenting
cells (APCs) in the form of dendritic cells (DCs), and to
assess immune responses to specific tumor epitopes using
tetramer and ELISPOT assays [38]. These advances allied to
the development of genetically modified mouse models have
led to a deeper understanding of the interactions between
cancer and the immune system of the host [39]. Indeed,
the available experimental evidence supports the hypothesis
that once tumors have become clinically apparent their
immunogenicity has been modified by the selective pressure
of the immune system, resulting in the growth of tumors
that are characteristically poorly immunogenic, being able to
escape immune detection, and/or to actively inhibit immune
effectors [39]. Furthermore, it is clear that, although T
cells become tolerant to many self-antigens in the thymus,
which depletes the pool that might react to cancer, tolerance
to many self-components is actively maintained in the
periphery by several mechanisms. For example, immature
DC presenting self-antigens to T cells are tolerogenic
and peripheral tolerance is maintained by Tregs subset
that can be innate or induced. Suppressor macrophages
form a final barrier to immune function and can result in
immune shutdown [40]. Peripheral tolerance can be broken
by “maturation” of DC in local sites that allow transient
immune responses to invading pathogens, but it leads to the
belief that if it were not for these regulatory mechanisms
T cells could respond better to “self-” antigens on tumors,
something for which there is now considerable evidence
[41].
The recognition of the fact that the host can break
a state of tolerance that has developed to its own tumor
offers many possibly effective immunotherapeutic strategies,
some being currently tested in clinical trials. The “danger”
model of immunity suggests that pathogens with associated
molecular patterns (PAMPs) and DAMPS engender an
inflammatory milieu that promotes the development of
antigen-specific immunity through DC maturation that
allows internalization of apoptotic and necrotic cellular
debris and presentation of processed antigen to T cells. Thus,
administration of radiation may therefore be considered to
create an inflammatory setting via DCmaturation, induction
of apoptosis, necrosis, cell surface molecules, and secretory
molecules. As with many other challenges, radiation upreg-
ulates expression of immunomodulatory surface molecules
(MHC, costimulatory molecules, adhesion molecules, death
receptors, heat shock proteins) and secretory molecules
(cytokines, inflammatory mediators) in tumor, stromal, and
vascular endothelial cells. Important amongst these may be
the upregulation of TNF family members that could promote
cell killing, not only by TNF in the microenvironment but
also by radiation-induced TNF.
6. Can Radiobiologic Models Be Adapted to
Account for Other Modes of Tumor Response
at High Dose Per Fraction?
Therefore, the evidence would seem to suggest that there are
several potential immunologic mechanisms for cell killing in
the high-dose range. The LQmodel has long been considered
to overestimate radiation cell killing at these doses as a
consequence of the model’s prediction of a continuous
downward bend (ßd2) in the survival curve. While in vivo
data are sparse, the dose-response may be linear above
12Gy [42], and two-component or other models have been
described that may better predict the response at dose per
fraction above 5–7Gy. For example, Park et al. [5] described
the effects of radiation in the ablative dose range using
a universal survival curve (USC) model, which combines
the LQ and multitarget models using a transition dose to
separate the two fitting components of the model. Using the
LQ model, the potency of the doses used in the Indiana
University phase II trial of SABR for medically inoperable
NSCLC (20Gy × 3) was estimated to be 1.7 times greater
than the biological effectiveness of a similar Japanese trial
delivering 12Gy × 4. However, when the USC model was
used, the potency of the Indiana University regimen was
only 1.34 times more than the Japanese regimen [5]. Other
models have included the generalized LQ (gLQ) model in
which the reduction of conversion of sublethal to lethal
injury in hypofractionated ablative dose radiation is taken
into account and the actual effect of the radiation is lower
than what was estimated by the LQ model [43]. However,
modeling may never fully describe the complexity of the
biological processes involved in the response to high dose per
fraction radiation, but it might facilitate the ability to design
optimal radiosurgery treatment plans once sufficient clinical
data have been obtained. From a radiobiological perspective,
what is clear is that there are processes that are different at
high from low dose per fraction and these include the ability
of cells to progress through the cell cycle, the likelihood of cell
death perhaps with a different mechanism, vascular effects,
proinflammatory effects, and immune effects.
7. Local Radiation Enhancement of
Systemic Immunity
It is clear from what has been said that localized cancer
has systemic immune effects as does RT. It is also clear that
the outcome of cancer and cancer therapy depends heavily
upon the nature of the cells that are generated, in particular
with respect to metastasis and overall survival. It seems likely
that unexpected discrepancies in the relative efficacies of
different anticancer regimens and divergence or convergence
between regional and distant failures could be due to such
systemic influences, for example, of local tumor control on
the incidence of distance metastasis. Future studies aimed
at assessing the predictive value of systemic responses in
the response of cancer to different dose schedules of RT
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are likely to be very informative, and strategies that target
systemic innate and cancer and radiation-induced regulatory
mechanism hold great promise. These strategies, together
with DC-based and other forms of antitumor vaccination,
can greatly modify the total radiation dose required to
achieve local control as well as influencing distant disease,
and RT should adapt to optimally integrate with such
approaches. While most chemotherapy regimens are thought
to compromise the immune system, they also can have
immunomodulatory effects that require study.
8. Conclusions
Searching for references on PubMed that contain “SBRT”
or “SABR” and “biology” reveals very few hits emphasizing
that this is an area of modern radiotherapy where detailed
understanding biology needs to catch up with the clinic [44].
Small animal platforms are now developed to simulate a
realistic SABR delivery in experimental animals [45] and
other recent developments in image-guided small animal
irradiators could also be adapted to simulate SABR [46].
A wealth of knowledge already exists in the radiobiology
archive from the ‘60s, ‘70s, and ‘80s where large doses per
fraction were used for ease of experimental design in experi-
mental studies, which needs to be revisited. In the meantime,
combination immunotherapy and radiation approaches are
being translated into the clinic [47]. Currently, combina-
tion immunotherapy and radiation approaches are being
translated into the clinic where intratumoral dendritic cell
injection with coordinated irradiation and introduction of
autologous, unmanipulated dendritic cells has been the
subject of sarcoma therapy [48].
At present, SABR represents an exciting, effective,
yet empirically designed radiation therapy. Increasing our
knowledge of the underlying biology associated withmodern
high-dose delivery will only serve to improve the thera-
peutic benefit of this modality. In addition, we believe that
SABR could be optimized for use with immunotherapeutic
approaches so as to better generate tumor antigen-specific
cellular immunity.
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